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patients with inoperable HCC (N=30) received single trans-
arterial chemoembolization (TACE) followed by volumetric-
modulated arc radiotherapy (VMAT)-based SBRT applying the 
van Herk margin recipe with mid-ventilation concept. Doses 
of SBRT were individualized according to normal tissue 
constraints. Tumor localization was performed by 4D CBCT 
using lipiodol as surrogate. Tumor responses were assessed by 
CT images using RECIST criteria every 3 months in the first 
year. In-field recurrence was defined as recurrence within 
the high-dose region (80% isodose volume). Overall survival, 
progression-free survival and local control rates were 
evaluated by the Kaplan-Meier method. Toxicities were 
graded according to CTCAE version 4.  
Results: Median follow-up time was 12 months (range: 4.2–
30.6 months). Patients’ characteristics were as follows: 
Median age (61 years, range: 28-87); Male/ female (n= 28/2); 
Child-Pugh class A/B (n= 28/2); ECOG 0-1/2 (n=21/9); BCLC 
stage A/B/C (n= 2/14/14); TNM stage I/II/III/IV 
(n=10/0/17/3); Solitary/ Multifocal (n=20/10); Portal vein 
thrombosis (n=8). Median size of tumor was 12.7cm (range: 
4.4-19.7cm) and Median GTV size was 937cc (range: 81-
3218cc). Median dose (2Gy equivalent, a/b=3) was 75Gy 
(range: 56-140Gy). Overall objective response rate was 67% 
(CR: n=1, PR: n=19). The 1-year in-field control, overall 
survival (OS) and progression-free survival (PFS) rate was 
86%, 65% and 42% respectively. Median survival not yet 
reached. Treatments were well tolerated. No grade 4-5 
toxicities were observed. Most common grade 3 toxicities 
were elevation of liver enzymes (n=6, 20%) and 
thrombocytopenia (n=1, 3%). No patient developed radiation-
induced liver disease (RILD).  
Conclusions: 4DCBCT guided SBRT using lipidiol as surrogate 
for tumor localization is feasible for inoperable HCC patients. 
It is safe, well tolerated and achieves high in-field control 
rate.  
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Purpose/Objective: Neo-adjuvant chemoradiotherapy (neo-
CRT) followed by surgery is currently the standard curative 
treatment for esophageal cancer. Both modalities may cause 
serious toxicity and morbidity. The aim of this study was to 
evaluate the incidence of pleural and pericardial effusion 
after neo-CRT followed by surgery and to investigate the 
impact on quality of life (QoL).  
Materials and Methods: Patients, that were included in a 
prospective trial to evaluate the impact of PET/CT for 
radiotherapy planning , underwent routine CT scanning 
during follow up in order to evaluate tumour recurrences. All 
these follow up CT's were blindly reviewed by a radiologist 
for signs of pleural and/or pericardial effusion. The degree of 
these toxicities was categorized as minor, moderate or 
severe. QoL questionnaires (EORTC QLQ-C30) were part of 
this follow up as well and were used to evaluate the impact 
of pleural and/or pericardial effusion . To investigate the 
relationship between pleural or pericardial effusion and the 
different domains of QoL a ANOVA was used. 
Results: Seventy-one patients were treated with neo-CRT and 
underwent routine CT scanning during follow up in absence of 
known recurrence and insufficient physical condition. The 
disease free survival (DFS) was 79%, 59% and 52% at 6, 12 and 
18 months after neo-CRT. At that time, 50, 42 and 35 
patients underwent follow up CT's. Pleural effusion occurred 
in 25 patients (50%) at 6 months and reduced over time; 33% 
at 12 months and 31% at 18 months. The degree was minor, 
moderate and severe in 11, 10 and 4 patients at 6 months. At 
18 months severe pleural effusion was still present in 3 
patients (9%). Pericardial effusion was seen in only 3 patients 
(6%) and completely reduced over time; 2.4% at 12 months 
and 0% at 18 months. Both pleural and pericardial effusion 
seemed of non-malignant origin, except for one patient with 
progressive malignant pleural effusion. Pleural effusion had a 
significant impact on physical functioning (p=0.001) and 
significantly enhanced dyspnoea (p=0.02). The mean score 
for physical functioning was 69 (SD: 26.3) in patients with 
pleural effusion vs. 82 (SD: 14.3) in absence of pleural 
effusion. Furthermore, pericardial effusion was significantly 
related to decreased global health status (39 vs. 75, p 
 
 
 
Conclusions: Pleural effusion is frequently observed after 
neo-CRT followed by surgical resection and improved over 
time and persisted up to 18 months pleural in 31% of the 
patients. Pericardial effusion is less common. Both pleural 
and pericardial effusions have a significant impact on QoL in 
terms of decreased physical functioning and increased 
dyspnoea.  
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Purpose/Objective: Locally-advanced pancreatic 
adenocarcinoma (LAPC) has a poor prognosis with up to 30% 
progressing locally following chemoradiotherapy (CRT). From 
surgical series, it is known that pancreatic tumours are 
hypoxic. As tumour hypoxia is associated with 
chemoradioresistance, selective radiotherapy dose escalation 
to a known hypoxic subvolume may improve rates of local 
control and spare excess toxicity to adjacent normal tissue. 
Fluoromisonidazole is selectively reduced and retained in 
hypoxic cells and its uptake correlates with needle electrode 
measured hypoxia. However, there have been no reports of 
the successful application of FMISO-PET/CT in pancreatic 
cancer. We assessed the utility of 18F-fluoromisonidazole 
(FMISO)-PET/CT for characterising hypoxia in LAPC with the 
aim of generating spatially consistent biological target 
volumes (BTVs) that could be used for radiotherapy dose 
escalation. 
Materials and Methods: 6 patients from an ethically-
approved clinical trial in LAPC had 2 FMISO-PET/CTs 6-7 days 
apart in the week prior to starting CRT.The GTV was defined 
on contrast-enhanced CT (CECT) with the patient 
immobilised in the radiotherapy treatment position. This 
position was replicated for FMISO-PET/CT scanning. The CECT 
was rigidly registered to the CT component of the FMISO-
PET/CTs, prioritising matching of the tumour. The GTV was 
propagated to the FMISO-PET/CTs. FMISO uptake 
quantification and tumour segmentation were performed 
using the PET image acquired 4 hours post-tracer injection. 
The SUVpeak (the 1cm3 sphere volume of interest (VOI) with 
the highest mean activity within the GTV) at each timepoint 
was delineated. The centre of mass of the GTV on both 
FMISO-PET/CTs was aligned and the distance between the 
centres of mass of the SUVpeak at both time points was 
calculated. A hypoxic boost volume was segmented on the 
second FMISO-PET/CT, using the thresholds tumour:muscle 
(T:M) >1.3 and tumour:blood (T:B) >1.4 . 
Results: The mean tumour volume was 23.0 cm3 (range 11.3-
34.9 cm3). There was no significant difference in maximum, 
mean or median SUV, T:M or T:B between scans when 
quantified across the whole GTV or the SUVpeak VOI. The mean 
distance between the centres of mass of the SUVpeak on the 
two FMISO-PET/CTs was 2.4 mm (range 0.5-6.8 mm). It was 
less than 3mm in 5/6 patients which is similar to the spatial 
resolution of the PET scan. The subvolumes defined by a 
T:M>1.3 and T:B>1.4 covered a mean of 34.8% (range 1.8-
83.4%) and 14.6% (range 0.8-42%) of the GTV respectively. 
Conclusions: To our knowledge, this is the first report of 
sequential FMISO-PET/CT successfully characterising hypoxia 
in LAPC. Our proposed method of segmenting the tumour to 
delineate a hypoxic BTV produces volumes that are smaller 
than the GTV, but large enough to allow for dose escalation. 
The region of peak FMISO-uptake is spatially consistent over 
6-7 days. 
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Purpose/Objective: In rectal cancer patients treated with 
radiotherapy, prediction models could help to calculate 
probabilities for various outcomes, e.g. pathologic complete 
remission (pCR), disease-free survival, or various toxicities. 
Although model development and validation in trials can 
determine the performance of prediction models, we cannot 
expect the same performance in clinical practice. Not only 
because trial datasets do not necessarily represent the 
clinical population, but also because prediction model 
features are not always readily available in clinical practice 
and need to be (often manually) extracted from multiple 
sources. In this abstract, we present a semi-automatic 
method to collect features for prediction model application 
in clinical practice. As a secondary aim, we apply this method 
to validate a rectal cancer pCR prediction model (PMID: 
21176986) in routine clinical data. 
Materials and Methods: We started by identifying the sources 
of the prediction model features. The clinical and 
pathological TNM stages could be found in the electronic 
medical record (EMR). The tumor length was based on 
magnetic resonance imaging (MRI), and therefore only 
available in the free text diagnostic MRI report. The second 
step involved extracting features from the source systems 
(EMR and free text reports), and storing them in a Semantic 
Web data store. We used the Radiation Oncology Ontology 
(ROO) as our standardized terminology, in combination with 
Semantic Web technology to link extracted data from both 
sources (Figure 1). In the third step, we executed a query on 
the extracted data, and applied the prediction model on the 
query result. Finally, the area under the Receiver Operating 
Characteristic curve (AUC) was calculated to determine the 
discriminative power of the prediction model. 
 
 
Results: After querying our data store, we found 2579 rectal 
cancer patients, where 38 patients matched all features and 
outcomes (clinical and pathological TN, and tumor length) to 
